Keytruda-Lynparza Combo Misses Primary Goal in BRCA Pancreatic Cancer

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers reported that maintenance treatment with Keytruda (pembrolizumab) plus Lynparza (olaparib) showed signs of clinical activity but did not meet its primary efficacy goal in patients with germline BRCA1- or BRCA2-mutated metastatic pancreatic cancer.

Findings from the phase 2 SWOG S2001 trial suggest that combining immunotherapy with targeted therapy may benefit some patients, although additional research is needed to determine which individuals are most likely to respond.

" The rationale for this trial came from the need to deepen and sustain responses beyond what was observed in the POLO trial," Dr. Vincent Chung, a medical oncologist at City of Hope, said in an interview with CURE.

Can Keytruda Improve Outcomes?

Lynparza is currently a standard maintenance treatment option for patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed following platinum-based chemotherapy. However, previous research demonstrated an improvement in progression-free survival without a corresponding improvement in overall survival, prompting investigators to explore new strategies.

Researchers designed SWOG S2001 to evaluate whether adding Keytruda to Lynparza maintenance could improve outcomes compared with Lynparza alone.

Patients were randomly assigned to receive either the combination of Keytruda plus Lynparza or Lynparza by itself. Investigators planned to enroll 88 patients and sought to improve median progression-free survival from 7 months to 11.7 months.

According to Chung, scientific evidence suggested the combination could be beneficial because PARP inhibition may make tumors more susceptible to immunotherapy. Previous laboratory research has shown that PARP inhibitors can increase PD-L1 expression and activate the STING pathway, potentially helping the immune system recognize and attack cancer cells more effectively.

Although the study was stopped early after a planned futility analysis, investigators observed encouraging signals of activity.

The overall response rate was 28% among patients treated with Keytruda plus Lynparza compared with 18% among those who received Lynparza alone. Median progression-free survival was 8.2 months in the combination arm versus 6.4 months in the Lynparza-alone arm.

While these results did not reach the study's predefined goal, they suggest that some patients may derive additional benefit from the combination approach.

For patients and families affected by BRCA-mutated pancreatic cancer, the findings highlight ongoing efforts to improve outcomes through personalized treatment strategies that target specific genetic alterations.

Future of Targeted Therapy

Although SWOG S2001 did not meet its primary end point, the findings contribute to a growing body of research supporting biomarker-driven treatment approaches in pancreatic cancer.

Historically, pancreatic cancer has been difficult to treat with both immunotherapy and targeted therapies. However, patients whose tumors harbor inherited BRCA mutations represent an important subgroup in which precision medicine strategies have shown promise.

Chung pointed to findings from the POLAR trial, which evaluated Keytruda plus Lynparza in patients with germline BRCA1, BRCA2 or PALB2 mutations. That study reported an overall response rate of approximately 35% and an overall survival of roughly 23 months.

Because SWOG S2001 is the first randomized study to directly compare the combination with Lynparza maintenance alone, the trial provides important information about the potential role of combining PARP inhibition with immunotherapy.

One of the most important next steps, according to Chung, will be identifying biomarkers that can help predict which patients are most likely to benefit from treatment.

Researchers collected blood and tumor tissue samples during the study, and planned correlative analyses may provide additional insight into why some patients responded while others did not.

"The correlative studies will be really important in terms of looking for biomarkers for prediction of response," Chung said.

For patients with metastatic pancreatic cancer, these findings underscore the importance of ongoing clinical trials focused on precision medicine. Although Keytruda plus Lynparza is not expected to change the current standard of care based on these results alone, the observed activity suggests that targeted therapy and immunotherapy combinations may continue to play an important role in future treatment development for carefully selected patient populations.

Trial Details

SWOG S2001 was a randomized phase 2 study evaluating maintenance Keytruda plus Lynparza versus Lynparza alone in patients with germline BRCA1- or BRCA2-mutated metastatic pancreatic cancer.

The study was conducted through a collaboration among SWOG, Alliance, ECOG-ACRIN and NRG Oncology.

The trial was designed to improve median progression-free survival from 7 months to 11.7 months but was closed early following a planned futility analysis.

References

1. Maintenance olaparib with or without pembrolizumab in germline BRCA1/2-mutated metastatic pancreatic cancer: results from SWOG S2001. Dr Vincent Chung. Presented at the 2026 ASCO Annual Meeting; Chicago, Illinois.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.